Section Arrow
MENS.NASDAQ
- Jyong Biotech Ltd
Quotes are at least 15-min delayed:2025/11/18 07:52 EST
Pre Market
Last
 30.89
+0.17 (+0.55%)
Bid
28
Ask
37.07
High 30.89 
Low 30.72 
Volume
Regular Hours
Last
 30.72
-7.47 (-19.56%)
Day High 
40.25 
Prev. Close
38.19 
1-M High
63 
Volume 
185.16K 
Bid
28
Ask
37.07
Day Low
29 
Open
40.25 
1-M Low
33.97 
Market Cap 
2.90B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 39.4 
20-SMA 46.24 
50-SMA 51.65 
52-W High 67 
52-W Low 6.0101 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.04/--
Enterprise Value
2.91B
Balance Sheet
Book Value Per Share
-0.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APLTApplied Therapeutics0.2842+0.0659+30.19%-- 
Pre Market 0.3048 +0.0206 +7.25%
GLMDGalmed Pharmaceuticals Ltd1.05+0.01+0.96%0.02PE
Pre Market 0.9697 -0.0803 -7.65%
CYPHCypherpunk Technologies Inc.2.43-0.32-11.64%-- 
Pre Market 2.41 -0.02 -0.82%
ASBPAspire Biopharma Holdings Inc.0.0913-0.015-14.11%-- 
Pre Market 0.1211 +0.0298 +32.64%
ANVSAnnovis Bio3.03+0.69+29.49%-- 
Pre Market 3.06 +0.03 +0.99%
Quotes are at least 15-min delayed:2025/11/18 07:52 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.